SEC Form 4 · accession 0001209191-18-051472
Xencor Inc · XNCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul A Foster
Officer — Chief Medical Officer
Period of report
Sep 17, 2018
Accepted (ET)
Sep 18, 2018 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326732
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 17, 2018 | M | 40,000 | $11.05 | A | 44,952 | D | |
| Common StockF2 | Sep 17, 2018 | S | 40,000 | $46.0302 | D | 4,952 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $11.05 | Sep 17, 2018 | M | 40,000 | D | — | Feb 20, 2024 | Common Stock | 40,000 | 10,000 | D |
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 17, 2018.
- F2The weighted average sale price for the transaction reported was $46.0302, and the range of prices were between $46.0121 and $46.0782. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- F3The stock option is fully vested.